SCHEMBL6755014

SCHEMBL6755014

CCCC(=O)N(Cc1nc2ccccc2n1C)c1ccc2sc(C(=O)N3CCN(CC)CC3)cc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.44
KDM4E B2RXH2 3/20 0.44
LMNA P02545 3/20 0.44
MAPT P10636 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
HRH3 Q9Y5N1 1/20 0.44
RXFP1 Q9HBX9 1/20 0.42
HRH4 Q9H3N8 1/20 0.41
HPGD P15428 2/20 0.41
GAA P10253 2/20 0.41
HTT P42858 1/20 0.41
TSHR P16473 1/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
DRD2 P14416 2/20 0.39
DRD3 P35462 2/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6758117 0.94 HRH4 (0.48) ALDH1A1KDM4ELMNAMAPTSMN1; SMN2
SCHEMBL6759310 0.89 ALDH1A1 (0.44) ALDH1A1KDM4ELMNAMAPTSMN1; SMN2
SCHEMBL6758252 0.87 ALDH1A1 (0.45) ALDH1A1KDM4ELMNAMAPTSMN1; SMN2
SCHEMBL6757422 0.84 ALDH1A1 (0.47) ALDH1A1KDM4ELMNAMAPTSMN1; SMN2
SCHEMBL6755065 0.83 KMT2A (0.47) ALDH1A1KDM4ELMNAMAPTSMN1; SMN2
SCHEMBL6760871 0.82 HRH4 (0.48) ALDH1A1KDM4ELMNANPC1RAB9A
SCHEMBL6759291 0.81 HRH4 (0.49) ALDH1A1KDM4ELMNAMAPTSMN1; SMN2
SCHEMBL6757428 0.80 HRH4 (0.46) ALDH1A1KDM4ELMNANPC1HRH4
SCHEMBL6758072 0.79 NPC1 (0.48) ALDH1A1KDM4ELMNAMAPTSMN1; SMN2
SCHEMBL6757317 0.77 SYK (0.44) ALDH1A1KDM4ESMN1; SMN2HRH4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040204417-A1 Novel benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl transferase proteins PIERRE FABRE MEDICAMENT (FR) 2004-10-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204417-A1 Novel benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl transferase proteins CBR1, CBR3, HCCS ALDH1A1 2558/4885KDM4E 2166/4885LMNA 2717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.